Patents by Inventor Friedemann Schmidt
Friedemann Schmidt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11827633Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: August 23, 2021Date of Patent: November 28, 2023Assignee: SanofiInventors: Dirk Gretzke, Olaf Ritzeler, Uwe Heinelt, Volkmar Wehner, Friedemann Schmidt
-
Publication number: 20220041596Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: August 23, 2021Publication date: February 10, 2022Inventors: Dirk GRETZKE, Olaf RITZELER, Uwe HEINELT, Volkmar WEHNER, Friedemann SCHMIDT
-
Patent number: 11130755Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: November 2, 2017Date of Patent: September 28, 2021Assignee: SANOFIInventors: Dirk Gretzke, Olaf Ritzeler, Uwe Heinelt, Volkmar Wehner, Friedemann Schmidt
-
Publication number: 20200095242Abstract: The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula (I), in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: November 2, 2017Publication date: March 26, 2020Applicant: SANOFIInventors: Dirk GRETZKE, Olaf RITZELER, Uwe HEINELT, Volkmar WEHNER, Friedemann SCHMIDT
-
Patent number: 9718825Abstract: The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: March 12, 2014Date of Patent: August 1, 2017Assignee: SANOFIInventors: Marc Nazare, Nis Halland, Friedemann Schmidt, Heinz-Werner Kleemann, Tilo Weiss, Joachim Saas, Carsten Struebing
-
Publication number: 20170163056Abstract: A multi-cell battery stack includes a microcontroller and a string of battery management and protection IC devices connected to one another in a daisy chain configuration. Each battery management and protection IC device can include a communication interface circuit that includes pairs of differential input signal lines, receivers including respective current comparator circuits to receive differential signals on the differential input signal lines, and transmitters to provide outgoing differential signals on the differential input signal lines. A digital circuit block allows signals to pass between the receivers and transmitters.Type: ApplicationFiled: February 21, 2017Publication date: June 8, 2017Inventors: Wolfgang Roeper, Hendrik Ahlendorf, Friedemann Schmidt
-
Patent number: 9614661Abstract: A multi-cell battery stack includes a microcontroller and a string of battery management and protection IC devices connected to one another in a daisy chain configuration. Each battery management and protection IC device can include a communication interface circuit includes pairs of differential input signal lines, receivers including respective current comparator circuits to receive differential signals on the differential input signal lines, and transmitters to provide outgoing differential signals on the differential input signal lines. A digital circuit block allows signals to pass between the receivers and transmitters.Type: GrantFiled: April 9, 2012Date of Patent: April 4, 2017Assignee: Atmel CorporationInventors: Wolfgang Roeper, Hendrik Ahlendorf, Friedemann Schmidt
-
Publication number: 20160175304Abstract: The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: November 23, 2015Publication date: June 23, 2016Inventors: Marc NAZARE, Nis HALLAND, Friedemann SCHMIDT, Tilo WEISS, Uwe DIETZ, Armin HOFMEISTER, Jean-Christophe CARRY
-
Publication number: 20160024097Abstract: The present invention relates to N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides of the formula I, wherein Ar, n, X, Z, R1, R2 and R3 have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: March 12, 2014Publication date: January 28, 2016Applicant: SANOFIInventors: Marc NAZARE, Nis HALLAND, Friedemann SCHMIDT, Heinz-Werner KLEEMANN, Tilo WEISS, Joachim SAAS, Carsten STRUEBING
-
Patent number: 9221828Abstract: The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: June 9, 2014Date of Patent: December 29, 2015Assignee: SANOFIInventors: Marc Nazare, Nis Halland, Friedemann Schmidt, Tilo Weiss, Uwe Dietz, Armin Hofmeister, Jean-Christophe Carry
-
Patent number: 9174993Abstract: The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula (I), (R2)n wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: GrantFiled: September 18, 2012Date of Patent: November 3, 2015Assignee: SANOFIInventors: Marc Nazare, Nis Halland, Friedemann Schmidt, Tilo Weiss, Uwe Dietz, Armin Hofmeister
-
Publication number: 20140288083Abstract: The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: SANOFIInventors: Marc Nazare, Nis Halland, Friedemann Schmidt, Tilo Weiss, Uwe Dietz, Armin Hofmeister, Jean-Christophe Carry
-
Publication number: 20130264881Abstract: A multi-cell battery stack includes a microcontroller and a string of battery management and protection IC devices connected to one another in a daisy chain configuration. Each battery management and protection IC device can include a communication interface circuit includes pairs of differential input signal lines, receivers including respective current comparator circuits to receive differential signals on the differential input signal lines, and transmitters to provide outgoing differential signals on the differential input signal lines. A digital circuit block allows signals to pass between the receivers and transmitters.Type: ApplicationFiled: April 9, 2012Publication date: October 10, 2013Applicant: ATMEL CORPORATIONInventors: Wolfgang Roeper, Hendrik Ahlendorf, Friedemann Schmidt
-
Publication number: 20130072493Abstract: The present invention relates to N-[4-(1H-pyrazolo[3,4-b]pyrazin-6-yl)-phenyl]-sulfonamides of the formula I, wherein Ar, R1, R2 and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds which modulate protein kinase activity, specifically the activity of serum and glucocorticoid regulated kinase (SGK), in particular of serum and glucocorticoid regulated kinase isoform 1 (SGK-1, SGK1), and are suitable for the treatment of diseases in which SGK activity is inappropriate, for example degenerative joint disorders or inflammatory processes such as osteoarthritis or rheumatism. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.Type: ApplicationFiled: September 19, 2011Publication date: March 21, 2013Applicant: SANOFIInventors: Marc NAZARE, Nis Halland, Friedemann Schmidt, Tilo Weiss, Uwe Dietz, Armin Hofmeister
-
Patent number: 7129788Abstract: A d.c. signal controlled oscillator includes a frequency-determining network having a control input and a modulation input. A phase regulating loop includes the oscillator and components that provide a control signal to the control input. A circuit apparatus for driving the oscillator includes a modulation generator that provides a modulation signal to the modulation input, and a circuit arrangement that autonomously generates a signal depending on and representing a slope of the modulation and provides this slope signal to the modulation generator, which generates the modulation signal dependent on the slope signal.Type: GrantFiled: April 27, 2004Date of Patent: October 31, 2006Assignee: Atmel Germany GmbHInventors: Juergen Eckert, Thorsten Fahlbusch, Burkhard Gehring, Hans-Werner Groh, Horst Haefner, Hermann Hammel, Michael Hecker, Gerald Krimmer, Reinhard Reimann, Wolfgang Roeper, Friedemann Schmidt, Juergen Schnabel, Wolfgang Schneider, Michael Vogt, Hans-Peter Waible
-
Publication number: 20040233009Abstract: A d.c. signal controlled oscillator includes a frequency-determining network having a control input and a modulation input. A phase regulating loop includes the oscillator and components that provide a control signal to the control input. A circuit apparatus for driving the oscillator includes a modulation generator that provides a modulation signal to the modulation input, and a circuit arrangement that autonomously generates a signal depending on and representing a slope of the modulation and provides this slope signal to the modulation generator, which generates the modulation signal dependent on the slope signal.Type: ApplicationFiled: April 27, 2004Publication date: November 25, 2004Applicant: ATMEL Germany GmbHInventors: Juergen Eckert, Thorsten Fahlbusch, Burkhard Gehring, Hans-Werner Groh, Horst Haefner, Hermann Hammel, Michael Hecker, Gerald Krimmer, Reinhard Reimann, Wolfgang Roeper, Friedemann Schmidt, Juergen Schnabel, Wolfgang Schneider, Michael Vogt, Hans-Peter Waible
-
Patent number: 5748425Abstract: In order to protect against any damage caused by electrostatic discharges, an integrated circuit layout is provided with at least one circuit connection which is connected via one of two diodes, respectively, to a first supply line and a second supply line. The diodes are reverse biased, i.e., one of them becomes conductive if a potential exists at the circuit connection that is either higher or lower than the supply potentials applying to the supply lines. The circuit layout is provided with an overvoltage suppression device connecting the two supply lines. The overvoltage suppression device is switched into a low impedance state by a steep rate increase or rise in a supply voltage applied between the supply lines such that a discharge current counteracting the increase in the supply voltage will flow via the overvoltage suppression device from the one supply line to the other supply line, and the discharge energy is converted into heat in the overvoltage suppression device.Type: GrantFiled: October 16, 1996Date of Patent: May 5, 1998Assignee: Temic Telefunken microelectronic GmbHInventors: Henrik Gutsch, Horst Hafner, Hermann Hammel, Friedemann Schmidt, Jurgen Schnabel